HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm — Neutral
HIMS GlobeNewsWire — June 25, 2025LOS ANGELES, June 25, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. (“Hims & Hers” or “the Company”) (NYSE: HIMS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
3 Silver Miner Stocks to Buy as Prices Soar — Positive
EXK FNLPF PAAS 24/7 Wall Street — June 25, 2025Silver prices have surged to decade-highs and have nearly doubled in the past five years.
Tesla's Europe sales plunge for 5th straight month over lingering Musk brand damage — Negative
TSLA New York Post — June 25, 2025Tesla's new car sales plummeted 27.9% in May from the year before, according to data from the European Automobile Manufacturers Association.
Puma Biotechnology: Updated Timelines And A Resurgence In Sentiment — Positive
PBYI Seeking Alpha — June 25, 2025Puma Biotechnology remains undervalued despite steady neratinib sales and a promising, though early-stage, pipeline. Neratinib's combination with trastuzumab deruxtecan shows intriguing signals, especially in pancreatic cancer, but pivotal data won't arrive until 2026. Alisertib's phase 2 trials in breast and lung cancer are ongoing, but lack of recent data keeps its potential speculative for now.
Paychex Stock Leads S&P 500 Decliners as Firm Posts Lower-Than-Expected Sales — Negative
PAYX Investopedia — June 25, 2025Paychex (PAYX) was the worst-performing stock in the S&P 500 Wednesday after the payroll and human resources services provider missed sales estimates as most of its gains came from its acquisition of human capital management software maker Paycor.
Will New Drugs Enable BMY to Offset the Impact of Generic Competition? — Neutral
BMY Zacks Investment Research — June 25, 2025BMY depends on Reblozyl, Opdualag and Breyanzi to offset revenue hits from generics and Medicare Part D impacts.
Sanofi's Experimental Transplant Rejection Drug Gets FDA Orphan Tag — Neutral
SNY Zacks Investment Research — June 25, 2025Sanofi's riliprubart gets FDA orphan drug status for organ transplant rejection, unlocking key development perks.
BTSG Raises 2025 Financial Outlook: What's Backing It? — Positive
BTSG Zacks Investment Research — June 25, 2025BrightSpring boosts 2025 guidance as Pharmacy and Provider segments post strong gains and margin initiatives take hold.
GEHC Stock Gains Post FDA's Nod for Vizamyl's Expanded Indications — Positive
GEHC Zacks Investment Research — June 25, 2025GE HealthCare gains FDA nod to expand Vizamyl's use, unlocking new diagnostic and therapy-monitoring capabilities.
CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? — Positive
CRSP NTLA Zacks Investment Research — June 25, 2025CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains.
Verizon Private 5G Network Gains Traction: Can it Boost Revenues? — Positive
VZ Zacks Investment Research — June 25, 2025VZ lands a multibillion-dollar deal to deploy Private 5G across the Thames Estuary, transforming key U.K. logistics and manufacturing hubs.
Toast vs. Lightspeed: Which POS Platform Stock Offers More Upside? — Positive
LSPD TOST Zacks Investment Research — June 25, 2025TOST and LSPD compete head-to-head in the hospitality tech space, making them key rivals in the booming POS market.
Boeing's BDS Unit Likely to Benefit From Iran-Israel Conflict — Neutral
BA Zacks Investment Research — June 25, 2025BA's deep ties with Israel and its defense portfolio could drive growth amid heightened Iran-Israel tensions.
Square Handheld Launches in the UK, Powering Growth for Restaurants — Neutral
XYZ Business Wire — June 25, 2025LONDON--(BUSINESS WIRE)--Square, the global technology company, has today announced the launch of Square Handheld in the UK, setting food and beverage sellers up for success as they enter the busy summer season. Square Handheld is the most powerful, portable point-of-sale device yet from Square and is being launched alongside a suite of industry-specific features and upgrades to empower UK businesses to move faster, deliver better customer experiences, and grow. “Light. Slimline. Fits in your p.
Carnival Corporation reported record Q2 revenues, operating income, and adjusted EBITDA in its Q2 earnings, outperforming management's prior guidance. Carnival's history of beats and raises makes me increasingly confident in its ability to meet my $7.49 billion EBITDA target for FY 2025. Carnival's deleveraging efforts are supported by increasing profitability and a substantial EBITDA flow-through rate.
Robotaxi Roll Out: Tesla, Uber And Waymo Take Diverging Roads To Autonomy — Neutral
GOOG GOOGL TSLA UBER Benzinga — June 25, 2025Robotaxis are taking to the roads, and the major players in the sector operate with distinctly different business models. Here's a look at how Tesla, Inc. TSLA, Uber Technologies, Inc. UBER and Waymo are making their mark on the future of transportation.
Palantir Stock Hits ATH, But Can the Rally Hold Without Volume? — Positive
PLTR MarketBeat — June 25, 2025Palantir Technologies Inc. NASDAQ: PLTR made a new all-time high (ATH) after a surge of more than 5% after the United States engaged in missile strikes against targets in Iran. The stock is up more than 48% in the last three months after a sell-off to start the year.
Microsoft's AI momentum fuels $600 price target as enterprise demand surges — Positive
MSFT Proactive Investors — June 25, 2025Wedbush has raised its price target on Microsoft Corp (NASDAQ:MSFT) to $600, up from $515, citing a surge in enterprise demand for artificial intelligence services through its Azure cloud platform and Copilot software suite. The broker, which maintains its "outperform" rating and includes the company on its Best Ideas list, described the current environment as Microsoft's "shining moment".
Top Sin Stocks for Savvy Investors: Profiting From the Unconventional — Positive
CZR PM Zacks Investment Research — June 25, 2025Sin stocks offer defensive growth, with steady demand across alcohol, tobacco and gambling sectors, wherein reputation takes a back seat.
Can Rivian Weather Falling Deliveries Amid Demand Uncertainty? — Negative
RIVN Zacks Investment Research — June 25, 2025RIVN slashes 2025 delivery outlook amid high uncertainty around consumer demand for high-priced vehicles.
